The company’s circVec 4.0 demonstrates unprecedented gene expression levels in heart and brain tissues to open new therapeutic opportunities across multiple organs.

A strategic research collaboration has been announced by Biogen and Dayra Therapeutics aimed at the discovery and development of oral macrocyclic peptides that could disrupt traditional antibody-based treatments.

The companies will leverage GSK’s scientific expertise with LTZ’s immune engager platform to develop new first-in-class MCE therapies for the treatment of hematologic cancers and solid tumors.

The company is creating a new flagship manufacturing hub in North Carolina that will enable end-to-end manufacturing of its key medicines in one geographic location.

Having secured a European Commercial CGMP Manufacturing License from FIMEA, Nanoform is now able to produce and control the quality of nanoformed APIs for Europe and other key markets.

A fundamental, digitally driven overhaul of bio/pharmaceutical manufacturing models are needed to meet the demands of current global supply chain pressures and rising complexity of novel therapeutics.

As a settlement is finally agreed upon for Purdue Pharma and the Sackler family, the pharma industry needs to increase transparency and accountability to ensure profits are not prioritized over public health again.

Backed by the expert team and cutting-edge resources of Re:Build Manufacturing, Ensorcell will offer innovative, high-quality scientific tools designed to accelerate discoveries and improve patient outcomes.

Yaohui Ji brings nearly two decades of leadership experience as BioDuro strengthens its integrated contract research, development, and manufacturing organization (CRDMO) platform for small and large molecule development.

A significant investment from Curewell Capital has been secured by Wilmington PharmaTech, providing growth capital to expand manufacturing and technology capabilities to accelerate drug development with U.S. manufacturing.

The USD 3 billion facility will expand the company’s capacity to produce oral medicines, enabling it to meet rising customer demand, and will also strengthen its global supply chain.

In a review of CPHI Frankfurt 2025, several event exhibitors chat about the trends making waves in the industry and highlight the importance of face-to-face collaborations and networking.

Given the current complexities and challenges facing large molecule biomanufacturing, senior leaders believe it is imperative for industry to redefine the rules of competition, improve innovation, and be more intelligently connected.

There are a variety of challenges facing the small molecule drug sector, from U.S. tariff challenges and regulatory uncertainty to the demands of latest wave of complexity, meaning that CDMOs must act as proactive strategic partners.

The CDMO has completed the expansion of its Pessano facility in Milan, Italy, adding increased packaging and warehousing capacity that has already been authorized by the AIFA and is producing validation and commercial batches.

Primary packaging requirements are evolving in line with development trends; however, flexible and easily integrated ready-to-use solutions are beneficial options, highlight Dr. Robert Lindner and Christoph Zauner from SCHOTT Pharma.

For Jacob Werlinger from Bend Bioscience, turning innovative concepts into reality requires CDMOs to not just be service providers but more of a strategic scientific partner that can help advance the concept to commercialization using the right science tools.

Implementation of three-dimensional (3D) cell culture nanofiber systems in industrial vaccine production offers much higher viral vaccine titers, greater scalability and improved process economy, but it will require tight collaboration with the industry to help speed up their wide adoption, stresses Laura Chirica from Cellevate.  

As geopolitical factors are driving a greater focus on U.S. manufacturing, many companies are seeking ways to improve productivity while keeping their products affordable for patients, highlights Russel Miller from Enzene.

Innovation is driving OSD into new frontiers, from orally delivered biologics and enhanced solubility to sustainable manufacturing and AI-driven formulation development, asserts Shahrzad Missaghi from Colorcon.